VEGFA and diabetic macular edema: Intravitreal ranibizumab (Lucentis, Genentech, South San Francisco, California, USA) was the first anti-VEGF agent approved by the US Food and Drug Administration (FDA) in 2006 for the treatment of diabetic macular edema (DME) [3].